Cargando…

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals

In this paper we evaluate the economic gains of a joint deployment of femtocells and macrocells for the provision of Long Term Evolution (LTE) mobile broadband services in urban environments. Frequency bands of 2.6 GHz and 900 MHz are analyzed and different parameters related to the business model a...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Valérie, TA, Thi Dieu Ngan, Mokhtari, Zahra, Guiguet, Marguerite, Miailhes, Patrick, Valantin, Marc-Antoine, Charlotte, Fréderic, Bertheau, Philippe, Molina, Jean-Michel, Katlama, Christine, Caumes, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941829/
https://www.ncbi.nlm.nih.gov/pubmed/25928565
http://dx.doi.org/10.1186/gb-2012-13-3-1234
_version_ 1783484605110681600
author Martinez, Valérie
TA, Thi Dieu Ngan
Mokhtari, Zahra
Guiguet, Marguerite
Miailhes, Patrick
Valantin, Marc-Antoine
Charlotte, Fréderic
Bertheau, Philippe
Molina, Jean-Michel
Katlama, Christine
Caumes, Eric
author_facet Martinez, Valérie
TA, Thi Dieu Ngan
Mokhtari, Zahra
Guiguet, Marguerite
Miailhes, Patrick
Valantin, Marc-Antoine
Charlotte, Fréderic
Bertheau, Philippe
Molina, Jean-Michel
Katlama, Christine
Caumes, Eric
author_sort Martinez, Valérie
collection PubMed
description In this paper we evaluate the economic gains of a joint deployment of femtocells and macrocells for the provision of Long Term Evolution (LTE) mobile broadband services in urban environments. Frequency bands of 2.6 GHz and 900 MHz are analyzed and different parameters related to the business model are considered for a 30% market share operator. Results show important benefits for the base case where the service is offered to fixed-broadband clients, up to 75%, for small bandwidths. It results feasible to attribute subscriber loop costs to the radio access network (RAN) costs, so that the service could be offered to non fixed-broadband clients, in both cases of closed access and open access femtocells. However, initial savings result notably reduced, up to 50% less than in the base case if closed access is adopted and up to 13% less for open access. Site reuse reduces the initial savings only in 3%.
format Online
Article
Text
id pubmed-6941829
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69418292020-03-24 Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals Martinez, Valérie TA, Thi Dieu Ngan Mokhtari, Zahra Guiguet, Marguerite Miailhes, Patrick Valantin, Marc-Antoine Charlotte, Fréderic Bertheau, Philippe Molina, Jean-Michel Katlama, Christine Caumes, Eric Genome Biol Research In this paper we evaluate the economic gains of a joint deployment of femtocells and macrocells for the provision of Long Term Evolution (LTE) mobile broadband services in urban environments. Frequency bands of 2.6 GHz and 900 MHz are analyzed and different parameters related to the business model are considered for a 30% market share operator. Results show important benefits for the base case where the service is offered to fixed-broadband clients, up to 75%, for small bandwidths. It results feasible to attribute subscriber loop costs to the radio access network (RAN) costs, so that the service could be offered to non fixed-broadband clients, in both cases of closed access and open access femtocells. However, initial savings result notably reduced, up to 50% less than in the base case if closed access is adopted and up to 13% less for open access. Site reuse reduces the initial savings only in 3%. BioMed Central 2013-01-15 2012 /pmc/articles/PMC6941829/ /pubmed/25928565 http://dx.doi.org/10.1186/gb-2012-13-3-1234 Text en © Ascierto et al; licensee BioMed Central Ltd. 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Martinez, Valérie
TA, Thi Dieu Ngan
Mokhtari, Zahra
Guiguet, Marguerite
Miailhes, Patrick
Valantin, Marc-Antoine
Charlotte, Fréderic
Bertheau, Philippe
Molina, Jean-Michel
Katlama, Christine
Caumes, Eric
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
title Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
title_full Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
title_fullStr Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
title_full_unstemmed Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
title_short Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
title_sort hepatic steatosis in hiv-hcv coinfected patients receiving antiretroviral therapy is associated with hcv-related factors but not antiretrovirals
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941829/
https://www.ncbi.nlm.nih.gov/pubmed/25928565
http://dx.doi.org/10.1186/gb-2012-13-3-1234
work_keys_str_mv AT martinezvalerie hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals
AT tathidieungan hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals
AT mokhtarizahra hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals
AT guiguetmarguerite hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals
AT miailhespatrick hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals
AT valantinmarcantoine hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals
AT charlottefrederic hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals
AT bertheauphilippe hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals
AT molinajeanmichel hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals
AT katlamachristine hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals
AT caumeseric hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals